Plain-English translation of NCT02343042 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called combined with standard cancer treatments for people with multiple myeloma, a type of blood cancer. The study wants to find the right dose of and see how well it works when paired with different existing medications. Researchers believe this combination might help more patients with this disease.
Multiple myeloma is a serious cancer that often comes back or stops responding to initial treatment. This medication aims to help patients whose cancer has relapsed or become resistant to other drugs, and potentially help newly diagnosed patients as well.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of 12 different treatment groups based on your diagnosis and treatment history. Most participants will take the medication by mouth once or twice per week, combined with other standard cancer drugs, in 28–35 day cycles. You'll have regular clinic visits for blood tests, physical exams, and to receive treatment, and the study will last until your disease progresses or you cannot tolerate the treatment.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States